Biomerieux Sa Stock Price To Earnings To Growth
| BIM Stock | EUR 116.90 0.60 0.52% |
Biomerieux SA fundamentals help investors to digest information that contributes to Biomerieux's financial success or failures. It also enables traders to predict the movement of Biomerieux Stock. The fundamental analysis module provides a way to measure Biomerieux's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomerieux stock.
Biomerieux |
Biomerieux SA Company Price To Earnings To Growth Analysis
Biomerieux's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Biomerieux Price To Earnings To Growth | 2.90 X |
Most of Biomerieux's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomerieux SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Biomerieux SA has a Price To Earnings To Growth of 2.9045 times. This is 309.08% higher than that of the Healthcare sector and 225.74% lower than that of the Diagnostics & Research industry. The price to earnings to growth for all France stocks is 40.6% higher than that of the company.
Biomerieux Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomerieux's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomerieux could also be used in its relative valuation, which is a method of valuing Biomerieux by comparing valuation metrics of similar companies.Biomerieux is currently under evaluation in price to earnings to growth category among its peers.
Biomerieux Fundamentals
| Return On Equity | 0.18 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 11.4 B | |||
| Shares Outstanding | 118.37 M | |||
| Shares Owned By Insiders | 64.28 % | |||
| Shares Owned By Institutions | 18.57 % | |||
| Price To Earning | 35.41 X | |||
| Price To Book | 3.27 X | |||
| Price To Sales | 3.28 X | |||
| Revenue | 3.38 B | |||
| Gross Profit | 1.96 B | |||
| EBITDA | 1.01 B | |||
| Net Income | 601.1 M | |||
| Cash And Equivalents | 280.1 M | |||
| Cash Per Share | 2.38 X | |||
| Total Debt | 362.8 M | |||
| Debt To Equity | 27.30 % | |||
| Current Ratio | 1.71 X | |||
| Book Value Per Share | 29.31 X | |||
| Cash Flow From Operations | 811.1 M | |||
| Earnings Per Share | 4.66 X | |||
| Price To Earnings To Growth | 2.90 X | |||
| Target Price | 107.8 | |||
| Number Of Employees | 12.08 K | |||
| Beta | 0.16 | |||
| Market Capitalization | 11.04 B | |||
| Total Asset | 4.62 B | |||
| Retained Earnings | 949 M | |||
| Working Capital | 407 M | |||
| Current Asset | 1.1 B | |||
| Current Liabilities | 689 M | |||
| Z Score | 18.0 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 0.74 % | |||
| Net Asset | 4.62 B | |||
| Last Dividend Paid | 0.85 |
About Biomerieux Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomerieux SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomerieux using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomerieux SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Biomerieux Stock
Biomerieux financial ratios help investors to determine whether Biomerieux Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biomerieux with respect to the benefits of owning Biomerieux security.